STAT+: With new study data, Intra-Cellular could expand use of approved mood-disorder treatment
Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results from a new clinical trial that could potentially expand use of its drug to other…
Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results from a new clinical trial on Tuesday that could potentially expand use of its drug to other types of mood disorders.
Sales of the Intra-Cellular drug, called Caplyta, tripled last year to $249 million. The new study results, while not definitive, bolster confidence that the drug could also prove effective for people with major depressive disorder and so-called mixed features.
What's Your Reaction?
